{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T22:02:40Z","timestamp":1768860160006,"version":"3.49.0"},"reference-count":34,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"General Program of Jiangsu Provincial Health Commission","award":["M2021093"],"award-info":[{"award-number":["M2021093"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Epithelioid glioblastoma (EGBM, classified as glioblastoma, IDH wild type, grade 4 according to the fifth edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) (WHO CNS5)) is a highly aggressive malignancy, with a median progression-free survival (mPFS) of about 6 months in adults. The application of tumor-treating fields (TTFields, possessing anti-cancer capabilities via anti-mitotic effects) in the maintenance of temozolomide (TMZ) chemotherapy showed a benefit for prolonging the mPFS of newly diagnosed glioblastoma (GBM) for patients for up to 6.9 months in the EF-14 clinical trial (NCT00916409). However, studies focusing on the effect of TTFields in EGBM treatment are very limited due to the rarity of EGBM. Here, we have reported a case of a 28-year-old male (recurrent left-sided limb twitching for 1 month and dizziness for 1 week) diagnosed with EGBM. A right frontal lobe occupancy was detected by magnetic resonance imaging (MRI), and a total tumor resection was performed. Meanwhile, a postoperative histopathology test, including immunohistochemistry and molecular characterization, was conducted, and the results revealed a BRAF V600E mutation, no co-deletion of 1p and 19q, and negative O-6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Then, chemoradiotherapy was conducted, and TTFields and TMZ were performed sequentially. Notably, a long-term PFS of 34 months and a Karnofsky Performance Scale (KPS) of 90 were achieved by the patient on TTFields combined with TMZ, whose average daily usage of TTFields was higher than 90%.<\/jats:p>","DOI":"10.3390\/brainsci13040633","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T03:26:06Z","timestamp":1681097166000},"page":"633","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["TTFields Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report"],"prefix":"10.3390","volume":"13","author":[{"given":"Yuxuan","family":"Ding","sequence":"first","affiliation":[{"name":"The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 211166, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Jinling Hospital, Nanjing 210002, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feijiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jinling Hospital, Nanjing 210002, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianrui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Jinling Hospital, Nanjing 210002, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Jinling Hospital, Nanjing 210002, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Wang","sequence":"additional","affiliation":[{"name":"The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 211166, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.wneu.2019.08.007","article-title":"Confirming Diagnosis and Effective Treatment for Rare Epithelioid Glioblastoma Variant: An Integrated Survival Analysis of the Literature","volume":"131","author":"Lu","year":"2019","journal-title":"World Neurosurg."},{"key":"ref_2","first-page":"1529","article-title":"Clinicopathologic features and prognosis of epithelioid glioblastoma","volume":"13","author":"Wang","year":"2020","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.2147\/OTT.S249317","article-title":"Clinicopathological, Immunohistochemical and Molecular Genetic Study on Epithelioid Glioblastoma: A Series of Fifteen Cases with Literature Review","volume":"13","author":"Zeng","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-019-03212-0","article-title":"Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A\/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma","volume":"144","author":"Wang","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/bpa.12887","article-title":"Epithelioid glioblastoma with microglia features: Potential for novel therapy","volume":"30","author":"Nakagomi","year":"2020","journal-title":"Brain Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","article-title":"Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma a secondary analysis of a randomized clinical trial","volume":"4","author":"Taphoorn","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41582-022-00679-w","article-title":"Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours","volume":"18","author":"Horbinski","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1007\/s10143-021-01492-7","article-title":"Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma","volume":"44","author":"Sun","year":"2021","journal-title":"Neurosurg. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9586806","DOI":"10.1155\/2020\/9586806","article-title":"Multimodal MR Features of 8 Cases of Epithelioid Glioblastoma","volume":"2020","author":"Zhao","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1016\/j.wneu.2018.12.128","article-title":"The Radiological Imaging Features of Easily Misdiagnosed Epithelioid Glioblastoma in Seven Patients","volume":"124","author":"Huang","year":"2019","journal-title":"World Neurosurg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/neup.12459","article-title":"Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma","volume":"38","author":"Furuta","year":"2018","journal-title":"Neuropathology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bpa.12295","article-title":"Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas--Same Entity or First Cousins?","volume":"26","author":"Alexandrescu","year":"2016","journal-title":"Brain Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/bpa.12572","article-title":"BRAF V600E, TERT promoter mutations and CDKN2A\/B homozygous deletions are frequent in epithelioid glioblastomas: A histological and molecular analysis focusing on intratumoral heterogeneity","volume":"28","author":"Nakajima","year":"2017","journal-title":"Brain Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1002\/cncr.23899","article-title":"Epithelial and Pseudoepithelial Differentiation in Glioblastoma and Gliosarcoma: A Comparative Morphologic and Molecular Genetic Study","volume":"113","author":"Rodriguez","year":"2008","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus Radiotherapy\u2013Temozolomide for Newly Diagnosed Glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/neuonc\/nox025","article-title":"Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: A secondary analysis of EORTC and NRG Oncology\/RTOG","volume":"19","author":"Blumenthal","year":"2017","journal-title":"Neuro-Oncology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11060-022-04162-w","article-title":"Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: A retrospective analysis","volume":"160","author":"Wang","year":"2022","journal-title":"J. Neuro-Oncol."},{"key":"ref_21","first-page":"3873","article-title":"Prolonged administration of temozolomide in adult patients with anaplastic glioma","volume":"31","author":"Freyschlag","year":"2011","journal-title":"Anticancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.3171\/2014.9.FOCUS14502","article-title":"Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: A single-institution experience with as many as 101 temozolomide cycles","volume":"37","author":"Barbagallo","year":"2014","journal-title":"Neurosurg. Focus"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1200\/JCO.2018.78.9990","article-title":"BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study","volume":"36","author":"Kaley","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","article-title":"Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation\u2013Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I\/IIa Study","volume":"25","author":"Hargrave","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): A multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2217\/cns-2017-0006","article-title":"Dabrafenib and trametinib in BRAFV600E mutated glioma","volume":"6","author":"Brown","year":"2017","journal-title":"CNS Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40478-019-0774-7","article-title":"Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: Establishment and xenograft of a cell line to predict clinical efficacy","volume":"7","author":"Kanemaru","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/CAD.0000000000001130","article-title":"Effective treatment of a BRAF V600E-mutant epithelioid glioblastoma patient by vemurafenib: A case report","volume":"33","author":"Lin","year":"2021","journal-title":"Anti-Cancer Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Salvador, E., K\u00f6ppl, T., H\u00f6rmann, J., Sch\u00f6nh\u00e4rl, S., Bugaeva, P., Kessler, A.F., Burek, M., Ernestus, R.I., L\u00f6hr, M., and Hagemann, C. (2023). Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010185"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-6649-9-1","article-title":"Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)","volume":"9","author":"Kirson","year":"2009","journal-title":"BMC Med. Phys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/neuonc\/now182","article-title":"Tumor treating fields: A novel treatment modality and its use in brain tumors","volume":"18","author":"Hottinger","year":"2016","journal-title":"Neuro Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"110193","DOI":"10.1016\/j.biopha.2020.110193","article-title":"Tumor treating fields for high-grade gliomas","volume":"127","author":"Luo","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11060-021-03755-1","article-title":"PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma","volume":"153","author":"Dono","year":"2021","journal-title":"J. Neuro-Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"vdaa069","DOI":"10.1093\/noajnl\/vdaa069","article-title":"Current usage of tumor treating fields for glioblastoma","volume":"2","author":"Lassman","year":"2020","journal-title":"Neuro-Oncol. Adv."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/13\/4\/633\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:12:03Z","timestamp":1760123523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/13\/4\/633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["brainsci13040633"],"URL":"https:\/\/doi.org\/10.3390\/brainsci13040633","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]}}}